Curated News
By: NewsRamp Editorial Staff
August 23, 2024
New ALS Treatment Shows Positive Results in Clinical Trials
TLDR
- Clene's CNM-Au8 showed significant improvement in key biomarkers among ALS patients, potentially giving them a treatment advantage.
- The biomarker and efficacy data was submitted to the FDA for accelerated approval, targeting a Type C meeting request.
- CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, offering hope for earlier patient benefit.
- Clene's latest updates and findings were presented at the Canaccord Genuity 44th Annual Growth Conference.
Impact - Why it Matters
This news matters as it represents a potential breakthrough in the treatment of ALS, offering hope to patients and their families. The positive results and potential accelerated approval pathway could mean faster access to a new treatment option for those suffering from this devastating disease.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, announced positive results of two Phase 2 clinical trials of CNM-Au8 for the treatment of ALS. The trials showed significant improvement in key biomarkers, leading to a Type C meeting request with the FDA for an accelerated approval pathway. CEO Rob Etherington expressed optimism about CNM-Au8’s potential as a new ALS treatment.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, New ALS Treatment Shows Positive Results in Clinical Trials
